ORLANDO -- Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis previously untreated with a biologic, but the integrin receptor ...

A new study found cyclosporine was no more effective than infliximab in patients with acute, severe ulcerative colitis refractory to intravenous steroids, according to a report by Internal Medicine ...

The FDA has approved Remicade from Janssen Biotech to treat moderately to severely active ulcerative colitis in children over age 6 who responded inadequately to conventional therapy, according to an ...

LAS VEGAS -- In patients with inflammatory bowel disease who lost response after infliximab (Remicade) induction, escalating the maintenance dose of the subcutaneous infliximab biosimilar CT-P13 ...

Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.

JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...

Please provide your email address to receive an email when new articles are posted on . Use of a second anti-TNF — IV or subcutaneous agent — resulted in early response and long-term remission among ...

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA (infliximab-dyyb), a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative ...

LONDON, Dec 17 (Reuters) - Britain's healthcare cost-effectiveness watchdog NICE said on Wednesday it had recommended the use of Remicade as an option for treating acute exacerbations of ulcerative ...

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...

The US Food and Drug Administration (FDA) has approved infliximab-dyyb (Zymfentra, Celltrion USA) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn ...

LONDON (Reuters) - Healthcare cost-effectiveness watchdog NICE said on Wednesday it had recommended the use of Remicade as an option for treating acute exacerbations of ulcerative colitis. Remicade is ...